CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian guidelines for the treatment of hepatitis C infection in HIV-hepatitis C coinfected adults

Treatment of HIV-hepatitis C virus (HCV)-coinfected individuals is considerably more complex than the treatment of monoinfected individuals, due to several factors including interactions among medications and accelerated progression of liver disease. Since the first Canadian guidelines for the treatment of HIV-HCV coinfected patients were published in the Winter 2013 issue of the Journal, several new medications that show considerable promise for the treatment of HCV have become available in Canada. Thus, the authors provide an update to the 2013 guidelines and include updated recommendations for treatment that incorporate these new medications.

[1]  D. Neau,et al.  Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  K. Mounzer,et al.  Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. , 2014, JAMA.

[3]  X. Forns,et al.  Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. , 2014, Gastroenterology.

[4]  Riina Salupere,et al.  Sofosbuvir and ribavirin in HCV genotypes 2 and 3. , 2014, The New England journal of medicine.

[5]  X. Forns,et al.  ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. , 2014, The New England journal of medicine.

[6]  T. Hassanein,et al.  ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. , 2014, The New England journal of medicine.

[7]  Robert Herring,et al.  Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. , 2014, The New England journal of medicine.

[8]  O. Weiland,et al.  Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.

[9]  Sanjeev Arora,et al.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[10]  Brian L. Pearlman,et al.  O165 SIMEPREVIR PLUS SOFOSBUVIR WITH/WITHOUT RIBAVIRIN IN HCV GENOTYPE 1 PRIOR NULL-RESPONDER/TREATMENT-NAIVE PATIENTS (COSMOS STUDY): PRIMARY ENDPOINT (SVR12) RESULTS IN PATIENTS WITH METAVIR F3–4 (COHORT 2) , 2014 .

[11]  Z. Younossi,et al.  O7 ONCE-DAILY SIMEPREVIR (TMC435) PLUS SOFOSBUVIR (GS-7977) WITH OR WITHOUT RIBAVIRIN IN HCV GENOTYPE 1 PRIOR NULL RESPONDERS WITH METAVIR F0–2: COSMOS STUDY SUBGROUP ANALYSIS , 2014 .

[12]  A. Mangia,et al.  P1220 MODELING PREDICTS CLINICALLY MEANINGFUL SVR RATES IN GENOTYPE 1 TREATMENT-EXPERIENCED PATIENTS BASED ON RESULTS IN GENOTYPE 1 TREATMENT-NAIVE PATIENTS TREATED WITH SOFOSBUVIR + PEGINTERFERON + RIBAVIRIN FOR 12 WEEKS , 2014 .

[13]  A. Płotka,et al.  The Effects of Boceprevir and Telaprevir on the Pharmacokinetics of Maraviroc: An Open-Label, Fixed-Sequence Study in Healthy Volunteers , 2014, Journal of acquired immune deficiency syndromes.

[14]  M. Buti,et al.  Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C. , 2014, Gastroenterology.

[15]  H. Mo,et al.  Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial , 2014, The Lancet.

[16]  S. Zeuzem,et al.  Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. , 2014, Gastroenterology.

[17]  P. Thuluvath,et al.  Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. , 2014, The New England journal of medicine.

[18]  Brian L. Pearlman,et al.  svr results of a once-daily regimen of simeprevir (tmc435) plus sofosbuvir (gs-7977) with or without ribavirin in cirrhotic and non-cirrhotic Hcv genotype 1 treatment-naïve and prior null responder patients: The Cosmos study : lb-3 , 2013 .

[19]  M. Manns,et al.  Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naïve genotype 1 hepatitis C: The randomized PILLAR study , 2013, Hepatology.

[20]  D. Brainard,et al.  sofosbuvir in Combination With Pegifn and Ribavirin for 12 Weeks Provides High Svr Rates in Hcv-infected Genotype 2 or 3 Treatment Experienced Patients with and without Compensated Cirrhosis: Results from the Lonestar-2 Study : lb-4 , 2013 .

[21]  P. Colson,et al.  W48 Response Rate of Boceprevir-PegIFN-RBV in Treatment-Experienced HIV Coinfected Patients with HCV genotype 1: ANRS-HC27 BocepreVIH Study , 2013 .

[22]  Brad J. Wood,et al.  Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. , 2013, JAMA.

[23]  M. Buti,et al.  Faldaprevir and deleobuvir for HCV genotype 1 infection. , 2013, The New England journal of medicine.

[24]  V. Soriano,et al.  Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV , 2013, Annals of Internal Medicine.

[25]  K. Kaita,et al.  Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir/telaprevir in hepatitis C virus subgenotype 1a-infected patients from Manitoba. , 2013, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[26]  J. Mallolas,et al.  Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. , 2013, The Lancet. Infectious diseases.

[27]  E. Schiff,et al.  Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. , 2013, The New England journal of medicine.

[28]  John McNally,et al.  Sofosbuvir for previously untreated chronic hepatitis C infection. , 2013, The New England journal of medicine.

[29]  D. Nelson,et al.  845 ONCE DAILY SOFOSBUVIR PLUS RIBAVIRIN FOR 12 AND 24 WEEKS IN TREATMENT-NAÏVE PATIENTS WITH HCV INFECTION: THE QUANTUM STUDY , 2013 .

[30]  M. Manns,et al.  1413 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-2, A PHASE III TRIAL , 2013 .

[31]  A. Lok,et al.  1417 SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC) , 2013 .

[32]  E. O'Mara,et al.  Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  M. Blonk,et al.  Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  C. Stedman,et al.  Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. , 2013, The New England journal of medicine.

[35]  T. Pilot‐Matias,et al.  Exploratory study of oral combination antiviral therapy for hepatitis C. , 2013, The New England journal of medicine.

[36]  Lane R. Bushman,et al.  Pharmacokinetic Interaction Between Boceprevir and Etravirine in HIV/HCV Seronegative Volunteers , 2013, Journal of acquired immune deficiency syndromes.

[37]  M. Zazzi,et al.  Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. , 2012, The Journal of antimicrobial chemotherapy.

[38]  Anna Persson,et al.  Preliminary study of two antiviral agents for hepatitis C genotype 1. , 2012, The New England journal of medicine.

[39]  M. Ghany,et al.  An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases , 2011, Hepatology.

[40]  O. Weiland,et al.  Telaprevir for retreatment of HCV infection. , 2011, The New England journal of medicine.

[41]  Geoffrey Dusheiko,et al.  Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.

[42]  Stefan Zeuzem,et al.  Boceprevir for previously treated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.

[43]  J. Montaner,et al.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. , 2004, The New England journal of medicine.

[44]  Aniruddha M. Deshpande,et al.  Standardized Reporting of Clinical Practice Guidelines: A Proposal from the Conference on Guideline Standardization , 2003, Annals of Internal Medicine.

[45]  T. Chalmers.  American Association for the Study of Liver Diseases , 1959 .

[46]  Stefan Zeuzem,et al.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.

[47]  S. Shafran,et al.  CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. , 2013, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[48]  M. Bilodeau,et al.  An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. , 2012, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[49]  山崎 學,et al.  抗精神病薬の開発と今後--Janssen Pharmaceutical Companies研究所訪問記 , 2011 .

[50]  M. Manns,et al.  Boceprevir for untreated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.